Building frontier artificial intelligence to predict and reprogram the interactions between biochemical molecules.
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Eli Lilly and Company (Lilly) to accelerate biologics discovery using artificial intelligence.
Under the collaboration, Lilly will deploy Chai’s frontier AI platform to design novel biologic therapeutics for multiple targets. In addition, Chai will develop a purpose-built AI model, exclusively for use by Lilly, trained on large-scale proprietary Lilly data and tailored to Lilly’s discovery workflows. The collaboration follows a period during which a set of Chai’s model designs were evaluated by Lilly.